2024
Changes in Risk Tolerance for Ovarian Cancer Prevention Strategies during the COVID-19 Pandemic: Results of a Discrete Choice Experiment
Egleston B, Daly M, Lew K, Bealin L, Husband A, Stopfer J, Przybysz P, Tchuvatkina O, Wong Y, Garber J, Rebbeck T. Changes in Risk Tolerance for Ovarian Cancer Prevention Strategies during the COVID-19 Pandemic: Results of a Discrete Choice Experiment. Medical Decision Making 2024, 45: 168-176. PMID: 39722532, PMCID: PMC11881031, DOI: 10.1177/0272989x241302829.Peer-Reviewed Original ResearchConceptsHigher ovarian cancer riskRisk of ovarian cancerRisk-reducing surgeryOvarian cancer riskCancer prevention strategiesCancer riskPrevention strategiesOvarian cancerOvarian cancer prevention strategiesElevated risk of breastRisk of breastCOVID-19 pandemicPrevention scenariosInfluence patients' decisionsRisk-reducing strategiesMedical decision makingAge of menopauseDiscrete choice experimentPatient's decisionElevated riskGenetic testingCOVID-19Menopausal symptomsMedical CenterHeart disease
2020
Longitudinal follow-up after telephone disclosure in the randomized COGENT study
Kilbride M, Egleston B, Hall M, Patrick-Miller L, Daly M, Ganschow P, Grana G, Olopade O, Fetzer D, Brandt A, Chambers R, Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao X, Domchek S, Bradbury A. Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics In Medicine 2020, 22: 1401-1406. PMID: 32376981, PMCID: PMC7396300, DOI: 10.1038/s41436-020-0808-3.Peer-Reviewed Original ResearchConceptsDisclosure of genetic test resultsGenetic test resultsMedical follow-upEra of multigene panel testingGermline cancer genetic testingCancer genetic testingIn-person disclosureMultigene panel testingMedical management recommendationsFollow-upFollow-up appointmentsTelephone disclosureGenetic counselorsLongitudinal follow-upIn-personLongitudinal riskGenetic testingPanel testingParticipantsGenetic resultsBehavioral outcomesAssociated with sitesManagement recommendationsTD armIPDNCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Daly M, Pilarski R, Yurgelun M, Berry M, Buys S, Dickson P, Domchek S, Elkhanany A, Friedman S, Garber J, Goggins M, Hutton M, Khan S, Klein C, Kohlmann W, Kurian A, Laronga C, Litton J, Mak J, Menendez C, Merajver S, Norquist B, Offit K, Pal T, Pederson H, Reiser G, Shannon K, Visvanathan K, Weitzel J, Wick M, Wisinski K, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 380-391. PMID: 32259785, DOI: 10.6004/jnccn.2020.0017.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentHigh-risk assessmentGenetic testingNCCN Guidelines InsightsHereditary cancer syndromesHigh-penetrance genesNCCN panelNCCN guidelinesSystemic therapyAshkenazi Jewish ancestryMost recent recommendationsRelevant new dataPancreatic cancerOvarian cancerCancer syndromesRecent recommendationsCancerBreastSyndromeOvarianManagement recommendationsJewish ancestryRisk management recommendations
2018
Preferences for in‐person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study
Beri N, Patrick‐Miller L, Egleston B, Hall M, Domchek S, Daly M, Ganschow P, Grana G, Olopade O, Fetzer D, Brandt A, Chambers R, Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao X, Bradbury A. Preferences for in‐person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics 2018, 95: 293-301. PMID: 30417332, PMCID: PMC6453119, DOI: 10.1111/cge.13474.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCommunicationFemaleGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHereditary Breast and Ovarian Cancer SyndromeHumansMaleMiddle AgedNeoplastic Syndromes, HereditaryOutcome Assessment, Health CarePatient CompliancePatient PreferenceTelephoneTruth DisclosureConceptsIn-person disclosureGenetic test resultsCancer-specific distressTelephone disclosureIn-personIn-person communicationCommunication of genetic test resultsDisclosure of genetic test resultsCancer genetic testingMultigene panel testingDisclosure of resultsGeneralized anxietyPretest counselingDelivery modelsCommunication of resultsTelephone studyDeclined randomizationGenetic medicineGenetic testingTelephoneState anxietyDistressPanel testingAnxietyDepressionUse and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study.
Hall M, Patrick-Miller L, Egleston B, Domchek S, Daly M, Ganschow P, Grana G, Olopade O, Fetzer D, Brandt A, Chambers R, Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao X, Bradbury A. Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology 2018, 2: 1-12. PMID: 31819920, PMCID: PMC6901130, DOI: 10.1200/po.18.00199.Peer-Reviewed Original ResearchMultigene panel testingCommunication of genetic test resultsGenetic test resultsPatient-reported outcomesCancer-specific distressMultigene panelsGenetics providersState anxietyDisclosure of genetic test resultsTelephone studyCancer genetic testingIn-person disclosureHistory of cancerTargeted testingAshkenazi Jewish ancestryIn-personDemographic adjustmentCancer susceptibilityPre-disclosureGenetic knowledgeGenetic testingGenetic counselingLower anxietyJewish ancestryTelephoneRandomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results
Bradbury A, Patrick-Miller L, Egleston B, Hall M, Domchek S, Daly M, Ganschow P, Grana G, Olopade O, Fetzer D, Brandt A, Chambers R, Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao X. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal Of The National Cancer Institute 2018, 110: 985-993. PMID: 29490071, PMCID: PMC6136932, DOI: 10.1093/jnci/djy015.Peer-Reviewed Original ResearchConceptsIn-person disclosureMultigene panel testingGenetic test resultsTelephone disclosureIn-personPretest counselingSurgery intentionsEra of multigene panel testingCancer-specific distressCancer genetic testingGenetic testingGermline genetic testingState anxietyMultiple imputation analysisGeneralized anxietyPanel testingSubgroup analysisStatistically significant differenceSecondary subgroup analysisUsual careGenetic counselorsImputation analysisSecondary analysisSecondary outcomesConfidence intervals
2006
The incidence of BRCA1 and BRCA2 variants of unknown significance varies in different ethnic populations
Opatt D, Morrow M, Daly M. The incidence of BRCA1 and BRCA2 variants of unknown significance varies in different ethnic populations. Journal Of Clinical Oncology 2006, 24: 10002-10002. DOI: 10.1200/jco.2006.24.18_suppl.10002.Peer-Reviewed Original ResearchHistory of breast cancerGenetic testingAfrican American womenBreast cancerPersonal history of breast cancerGenetic counselingAfrican AmericansBRCA2 sequence alterationsIncidence of BRCA1Fox Chase Cancer CenterMutations of BRCA1Personal history of cancerWhite womenAmerican womenHistory of cancerAfrican American ethnicityPersonal historyClassification of VUSBRCA2 mutationsOvarian cancerBRCA2 variantsClinical dataInvasive breastBRCA2Increased risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply